Clinical Trials Logo

Liver Neoplasms clinical trials

View clinical trials related to Liver Neoplasms.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06404593 Completed - Colorectal Cancer Clinical Trials

Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases

Start date: June 18, 2019
Phase:
Study type: Observational

Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort underwent curative resection after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.

NCT ID: NCT06245785 Completed - Hepatic Cancer Clinical Trials

Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function

Start date: January 1, 2023
Phase:
Study type: Observational

Hepatic dysfunction limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. Established practice guidelines for patients with HCC and impaired liver function are lacking. The treatment allocation in these populations is heterogeneous and remains controversial. This study compared the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in patients with HCC and impaired liver function.

NCT ID: NCT06184841 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma

Start date: June 18, 2020
Phase: Phase 1
Study type: Interventional

Patients with liver metastasis from esophagus squamous (ESC) are usually offered systemic therapy. However, for those with predominant liver disease or failure of system therapy, local liver management becomes an option. This prospective single center study aimed to evaluate the efficacy and adverse events of hepatic arterial infusion chemotherapy (HAIC) using percutaneous catheter placement techniques for liver metastases from esophagus squamous (ESC).

NCT ID: NCT06118125 Completed - Advanced Cancer Clinical Trials

Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement

Start date: June 1, 2019
Phase:
Study type: Observational

Objective: the pre-hospital management of cancers is little known in General Medicine. The first lockdown related to the COVID-19 pandemic led to the closure of health facilities. Investigators were interested in the diagnosis and care pathway of digestive cancers in post-confinement in General Medicine in Nouvelle-Aquitaine.

NCT ID: NCT06038552 Completed - Liver Metastases Clinical Trials

The Long-term Efficacy of Imatinib With Hepatic Resection or Other Local Treatment for GIST Liver Metastases

Start date: January 1, 2002
Phase:
Study type: Observational

The goal of this observational study is to evaluate the overall survival benefits of local treatment combined with imatinib(IM) and IM alone in patients suffering from GIST liver metastases. The main question it aims to answer is: • Whether IM combined with hepatic resection (HR) or other local treatments such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) has better long-term survival benefits compared to IM monotherapy. Patients are divided into different treatment groups: - IM group - IM combined with HR group - IM combined with RFA or TACE group Researchers will compare the IM + HR group and IM + RFA/TACE group with the IM group to see if it has a better Overall survival (OS).

NCT ID: NCT06031129 Completed - Visceral Pain Clinical Trials

Butorphanol in Pain Following Ablation for Hepatic Tumor

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The objective of this investigation was to evaluate the influence of Butorphanol on postoperative pain mitigation in patients undergoing microwave ablation for hepatic tumor. Employing a rigorously designed multicentral, randomized, and placebo-controlled format, patients subjected to microwave ablation were assigned randomly to either Butorphanol (experimental group) or normal saline (control group). Primary outcomes encompassed intraoperative pain levels assessed through patient-driven evaluation utilizing a 10-point visual analog scale (VAS). Secondary outcomes included postoperative pain levels at the 6-hour mark (VAS) and comprehensive pain assessment outcomes.

NCT ID: NCT06013774 Completed - Liver Cancer Clinical Trials

Interventional X-ray and Scintigraphy Imaging of 99mTc-MAA During the Radioembolisation Pretreatment Procedure

IXSI
Start date: May 25, 2021
Phase: N/A
Study type: Interventional

To establish the safety and feasibility of interventional x-ray and scintigraphy imaging during the pre-treatment procedure of hepatic radioembolization

NCT ID: NCT05995990 Completed - Clinical trials for Colorectal Cancer Metastatic

Raman Spectroscopy for Liver Tumours Following Liver Surgery

Start date: November 25, 2020
Phase: N/A
Study type: Interventional

The aim of the proposed research is to develop a quick and reliable method for automated evaluation of tissue sections for residual tumour in histology specimens following liver surgery. This advanced technology will enable assessment of liver tumours and resection margins following liver surgery. The technology is based on Raman spectroscopy (RS) and multivariate spectral analysis to produce 2-dimensional biochemical images that can reliably separate the spectral signal of liver tumours from surrounding normal tissue.

NCT ID: NCT05907772 Completed - Cancer of Liver Clinical Trials

Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma

Start date: August 27, 2022
Phase:
Study type: Observational

This is a multi-center study in China to investigate the role of PIVKA-II in HCC recipient selection and prognostic stratification by analyzing the data of 522 recipients with HCC registered in the China Liver Transplant Registry.

NCT ID: NCT05848947 Completed - Clinical trials for Carcinoma, Hepatocellular

SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA

MAApping
Start date: April 25, 2023
Phase: Phase 4
Study type: Interventional

The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in patients who are undergoing evaluation for SIR-Spheres treatment for hepatocellular carcinoma.